Header Logo

Connection

JORGE E CORTES to Mutation

Back to Details
This is a "connection" page, showing publications JORGE E CORTES has written about Mutation.
JORGE E CORTES
Connection Strength
3.155
Mutation
  1. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia. Expert Rev Hematol. 2024 Jun; 17(6):211-221.
    View in: PubMed
    Score: 0.228
  2. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after =1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024 Jul; 38(7):1522-1533.
    View in: PubMed
    Score: 0.228
  3. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):348-355.
    View in: PubMed
    Score: 0.136
  4. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9.
    View in: PubMed
    Score: 0.113
  5. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3.
    View in: PubMed
    Score: 0.102
  6. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27; 120(13):2573-80.
    View in: PubMed
    Score: 0.101
  7. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 01; 118(23):5819-22.
    View in: PubMed
    Score: 0.099
  8. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood. 2010 Jul 01; 115(26):5428-9.
    View in: PubMed
    Score: 0.087
  9. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43.
    View in: PubMed
    Score: 0.081
  10. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S272-9.
    View in: PubMed
    Score: 0.079
  11. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11.
    View in: PubMed
    Score: 0.072
  12. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
    View in: PubMed
    Score: 0.047
  13. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020 11; 95(11):1296-1303.
    View in: PubMed
    Score: 0.044
  14. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700.
    View in: PubMed
    Score: 0.043
  15. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
    View in: PubMed
    Score: 0.043
  16. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
    View in: PubMed
    Score: 0.042
  17. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov 01; 125(21):3755-3766.
    View in: PubMed
    Score: 0.041
  18. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670.
    View in: PubMed
    Score: 0.038
  19. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797.
    View in: PubMed
    Score: 0.037
  20. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303.
    View in: PubMed
    Score: 0.037
  21. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695.
    View in: PubMed
    Score: 0.037
  22. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528.
    View in: PubMed
    Score: 0.034
  23. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na?ve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 07 10; 34(20):2333-40.
    View in: PubMed
    Score: 0.033
  24. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12.
    View in: PubMed
    Score: 0.032
  25. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016 Jan; 172(1):97-110.
    View in: PubMed
    Score: 0.032
  26. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70.
    View in: PubMed
    Score: 0.031
  27. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7.
    View in: PubMed
    Score: 0.031
  28. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015 Jul; 100(7):898-904.
    View in: PubMed
    Score: 0.030
  29. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
    View in: PubMed
    Score: 0.029
  30. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015 Jan; 168(1):69-81.
    View in: PubMed
    Score: 0.029
  31. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014 May 01; 20(9):2363-74.
    View in: PubMed
    Score: 0.028
  32. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9.
    View in: PubMed
    Score: 0.028
  33. Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. 2014 Jun; 55(6):1431-4.
    View in: PubMed
    Score: 0.027
  34. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73.
    View in: PubMed
    Score: 0.027
  35. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44.
    View in: PubMed
    Score: 0.027
  36. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6.
    View in: PubMed
    Score: 0.027
  37. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10; 31(29):3681-7.
    View in: PubMed
    Score: 0.027
  38. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
    View in: PubMed
    Score: 0.027
  39. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013 Oct; 98(10):1510-6.
    View in: PubMed
    Score: 0.027
  40. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62.
    View in: PubMed
    Score: 0.026
  41. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.
    View in: PubMed
    Score: 0.026
  42. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88.
    View in: PubMed
    Score: 0.026
  43. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9.
    View in: PubMed
    Score: 0.026
  44. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9.
    View in: PubMed
    Score: 0.025
  45. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5.
    View in: PubMed
    Score: 0.025
  46. Molecular targeted therapy in acute myeloid leukemia. Hematology. 2012 Apr; 17 Suppl 1:S59-62.
    View in: PubMed
    Score: 0.025
  47. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73.
    View in: PubMed
    Score: 0.024
  48. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15; 118(2):293-9.
    View in: PubMed
    Score: 0.023
  49. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21.
    View in: PubMed
    Score: 0.023
  50. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31; 117(13):3641-7.
    View in: PubMed
    Score: 0.022
  51. Competing cell clones in myeloproliferative neoplasm. Blood. 2010 Dec 02; 116(23):5074-5.
    View in: PubMed
    Score: 0.022
  52. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010 Aug 01; 116(15):3631-7.
    View in: PubMed
    Score: 0.022
  53. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010 Jan; 24(1):6-12.
    View in: PubMed
    Score: 0.021
  54. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009 Dec 03; 114(24):4944-53.
    View in: PubMed
    Score: 0.021
  55. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009 Sep 01; 27(25):4204-10.
    View in: PubMed
    Score: 0.020
  56. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009; 121(1):27-31.
    View in: PubMed
    Score: 0.020
  57. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun; 33(6):837-9.
    View in: PubMed
    Score: 0.019
  58. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008 Jul 15; 14(14):4392-9.
    View in: PubMed
    Score: 0.019
  59. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73.
    View in: PubMed
    Score: 0.019
  60. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer. 2008 Apr 15; 112(8):1744-53.
    View in: PubMed
    Score: 0.019
  61. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96.
    View in: PubMed
    Score: 0.018
  62. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008 Feb 06; 100(3):184-98.
    View in: PubMed
    Score: 0.018
  63. Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15; 110(6):2102-9.
    View in: PubMed
    Score: 0.018
  64. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci. 2007 Aug; 98(8):1223-5.
    View in: PubMed
    Score: 0.018
  65. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer. 2006 Oct 15; 107(8):1918-29.
    View in: PubMed
    Score: 0.017
  66. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006 Jul 01; 108(1):28-37.
    View in: PubMed
    Score: 0.016
  67. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023 05; 37(5):1048-1059.
    View in: PubMed
    Score: 0.013
  68. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.
    View in: PubMed
    Score: 0.011
  69. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132.
    View in: PubMed
    Score: 0.011
  70. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 12 12; 381(24):2315-2326.
    View in: PubMed
    Score: 0.010
  71. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1.
    View in: PubMed
    Score: 0.010
  72. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.
    View in: PubMed
    Score: 0.009
  73. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res. 2018 04; 67:67-74.
    View in: PubMed
    Score: 0.009
  74. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 01; 123(15):2875-2880.
    View in: PubMed
    Score: 0.009
  75. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug; 1(5):643-51.
    View in: PubMed
    Score: 0.008
  76. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73.
    View in: PubMed
    Score: 0.008
  77. Progress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):139-51.
    View in: PubMed
    Score: 0.007
  78. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.
    View in: PubMed
    Score: 0.007
  79. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):515-29.
    View in: PubMed
    Score: 0.007
  80. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40.
    View in: PubMed
    Score: 0.007
  81. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012 Dec 06; 120(24):4840-5.
    View in: PubMed
    Score: 0.006
  82. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45.
    View in: PubMed
    Score: 0.006
  83. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep; 26(9):2061-8.
    View in: PubMed
    Score: 0.006
  84. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95.
    View in: PubMed
    Score: 0.006
  85. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):361-6.
    View in: PubMed
    Score: 0.006
  86. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011 Mar; 96(3):347-9.
    View in: PubMed
    Score: 0.006
  87. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011 May 01; 117(9):1800-11.
    View in: PubMed
    Score: 0.006
  88. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011 May 15; 117(10):2145-55.
    View in: PubMed
    Score: 0.006
  89. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer. 2011 Feb 15; 117(4):662-76.
    View in: PubMed
    Score: 0.006
  90. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol. 2010 Oct; 47(4):371-80.
    View in: PubMed
    Score: 0.006
  91. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27.
    View in: PubMed
    Score: 0.006
  92. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010 Sep; 101(9):2005-10.
    View in: PubMed
    Score: 0.006
  93. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep. 2010 Apr; 5(2):70-80.
    View in: PubMed
    Score: 0.005
  94. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62.
    View in: PubMed
    Score: 0.005
  95. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010 Feb; 51(2):269-74.
    View in: PubMed
    Score: 0.005
  96. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010 Jun; 34(6):752-6.
    View in: PubMed
    Score: 0.005
  97. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009 Dec 17; 114(26):5271-8.
    View in: PubMed
    Score: 0.005
  98. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24.
    View in: PubMed
    Score: 0.005
  99. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6.
    View in: PubMed
    Score: 0.005
  100. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009 Aug 01; 27(22):3642-9.
    View in: PubMed
    Score: 0.005
  101. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18; 113(25):6322-9.
    View in: PubMed
    Score: 0.005
  102. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009 Apr; 16(2):122-31.
    View in: PubMed
    Score: 0.005
  103. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 02; 84(2):161-9.
    View in: PubMed
    Score: 0.005
  104. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008 Dec; 7(12):3834-41.
    View in: PubMed
    Score: 0.005
  105. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009 Apr 23; 113(17):3938-46.
    View in: PubMed
    Score: 0.005
  106. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood. 2008 Dec 15; 112(13):5190-2.
    View in: PubMed
    Score: 0.005
  107. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008 Sep 01; 112(5):1628-37.
    View in: PubMed
    Score: 0.005
  108. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9.
    View in: PubMed
    Score: 0.005
  109. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82.
    View in: PubMed
    Score: 0.004
  110. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Curr Hematol Malig Rep. 2007 May; 2(2):83-8.
    View in: PubMed
    Score: 0.004
  111. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007 Jan 15; 109(2):500-2.
    View in: PubMed
    Score: 0.004
  112. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res. 2006 Nov; 30(11):1365-70.
    View in: PubMed
    Score: 0.004
  113. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15; 354(24):2531-41.
    View in: PubMed
    Score: 0.004
  114. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15; 108(6):1809-20.
    View in: PubMed
    Score: 0.004
  115. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 01; 108(5):1497-503.
    View in: PubMed
    Score: 0.004
  116. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24.
    View in: PubMed
    Score: 0.004
  117. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008.
    View in: PubMed
    Score: 0.004
  118. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004 Apr 01; 22(7):1287-92.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.